Tvardi Therapeutics (TVRD) Company presentation summary

STAT3 as a therapeutic target

• STAT3 is a central mediator in inflammatory and proliferative diseases, driving both intrinsic (cellular) proliferation and extrinsic (immune) dysregulation.

• Inhibition of STAT3 shows disease modification in animal models and clinical proof of mechanism in idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).

• TTI-101 and TTI-109 are designed to target STAT3, with TTI-109 as a prodrug for improved delivery and tolerability.

Clinical pipeline and milestones

• TTI-101 is in Phase 2 for IPF and Phase 1b/2 for HCC, with topline data expected in 2H 2026.

• TTI-109 is in Phase 1 healthy volunteer studies, with topline data anticipated in 2Q 2026.

• The company has $25M in cash and expects its runway to last into Q4 2026.

IPF clinical results

• In the REVERT IPF trial, TTI-101-treated patients showed greater declines in fibrosis score and IL-6 levels compared to placebo.

• 63% of TTI-101 patients had increased FVC at 12 weeks, outperforming historical placebo groups.

• Adverse events were consistent with the IPF population, but GI side effects increased with concomitant nintedanib.